[Dexamethasone does not normalize disordered LH pulsatility in hyperandrogenemic ovarian insufficiency]

Area of Science:

• Endocrinology
• Reproductive Medicine
• Pharmacology

Context:

• Hyperandrogenemic ovarian failure (HOI) is a complex endocrine disorder.
• Dexamethasone (DEX) is used to manage HOI, particularly in cases of clomiphene resistance.
• Understanding DEX's impact on specific HOI subgroups is crucial for optimizing treatment.

Purpose:

• To evaluate the influence of adrenal androgen reduction via long-term dexamethasone (DEX) therapy on gonadotropin secretion in various hyperandrogenemic ovarian failure (HOI) subgroups.
• To investigate the effects of DEX on serum hormone levels and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) pulsatility in distinct HOI patient groups.

Summary:

• Dexamethasone (DEX) therapy significantly decreased serum levels of testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEA-S), and progesterone in all evaluated HOI subgroups.
• Mean LH concentrations showed minor decreases in DHEA-S elevated, high LH, and oligomenorrhea subgroups, with no significant changes in other groups.
• FSH levels and pulsatility remained largely unaffected by DEX therapy, while LH pulse frequency decreased only in the oligomenorrhea group.

Impact:

• DEX therapy demonstrates efficacy in reducing androgen excess in diverse HOI presentations.
• The findings suggest that DEX's primary benefit in HOI may stem from androgen suppression rather than direct modulation of gonadotropin pulsatility.
• This study provides valuable insights for tailoring DEX treatment strategies to specific patient profiles within the spectrum of HOI.